MediciNova, Inc.
NASDAQ:MNOVBiotechnology
-$0.02 today
- Market cap
- $68.14M
- Beta
- 0.62
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.24
Volume 0.12M
Average 0.04M
MNOV Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
MediciNova, Inc.NASDAQ: MNOV
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $1.26B rose 72466.5% year over year, ahead of the +18127.2% change in trailing-twelve-month research & development. Sequentially, it rose 74586.3% from the prior quarter. Over 3 fiscal years it compounded at -7.8% a year.
Context
- Research & development amounted to 1746.5% of revenue in FY2025.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +72466.5% holds above the trailing-twelve-month pace of +18127.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 7.15M USD
- Year-over-year change
- -0.6%
- 4-year CAGR
- -3.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.15M | -0.6% |
| FY2024 | 2024-12-31 | 7.2M | +27.2% |
| FY2023 | 2023-12-31 | 5.66M | -38.1% |
| FY2022 | 2022-12-31 | 9.14M | +12.9% |
| FY2021 | 2021-12-31 | 8.1M | — |
Research & Development vs competitors
How MNOV compares with its peers on the latest reported figures
- MNOV's LTM Mar 2026 research & development of $1.27B is the highest of the 11 companies compared; the peer median is $53.93M.
- Its year-over-year change of +18127.2% is the highest of 11, against a peer median of -8.6%.
- Research & development amounts to 212494.0% of revenue for MNOV, versus a peer median of 518.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.27B | +18127.2% | -7.8% | 212494.0% | |
| LTM Mar 2026 | $200.25M | +133.0% | +35.5% | 78.3% | |
| LTM Mar 2026 | $106.27M | -5.4% | +24.0% | 1163.2% | |
| LTM Mar 2026 | $86.08M | +3.9% | +4.8% | — | |
| LTM Mar 2026 | $67.7M | +8.5% | +10.6% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59.66M | -11.8% | +35.8% | — |
| LTM Mar 2026 | $48.2M | -55.0% | -0.4% | — | |
CBUSCibus, Inc. | LTM Mar 2026 | $41.12M | -18.1% | +56.4% | 959.3% |
| LTM Mar 2026 | $40.98M | +3.6% | +14.5% | — | |
| LTM Mar 2026 | $23.02M | -48.6% | -81.3% | — | |
| LTM Mar 2026 | $8.51M | -76.4% | -55.5% | 12.9% | |
| Peer median (excluding MNOV) | $53.93M | -8.6% | +12.6% | 518.8% | |
Competitors are the stored peer set for MNOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.04M | 0 | 1M | 0 | 409.66K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 378.61K |
| Gross Profit | 4.04M | 0 | 1M | 0 | 31.05K |
| Gross Margin | 100.0% | — | 100.0% | — | 7.6% |
| Research & Development | 8.1M | 9.14M | 5.66M | 7.2M | 7.15M |
| Selling, General & Admin | 5.72M | 5.48M | 5.24M | 5.48M | 6.16M |
| Operating Expenses | 14.25M | 14.63M | 10.9M | 12.68M | 13.31M |
| Depreciation & Amortization | 26.15K | 17.71K | 20.3K | 21.08K | 20.1K |
| EBITDA | (10.11M) | (14.05M) | (8.55M) | (11.02M) | (11.97M) |
| EBITDA Margin | -250.3% | — | -854.8% | — | -2922.4% |
| Operating Income | (10.22M) | (14.63M) | (9.9M) | (12.68M) | (13.28M) |
| Operating Margin | -253.0% | — | -990.0% | — | -3242.5% |
| Interest Income | 143.63K | 809.67K | 1.83M | 1.67M | 1.3M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 84.13K | 562.39K | 1.33M | 1.63M | 1.29M |
| Income Before Tax | (10.13M) | (14.07M) | (8.57M) | (11.04M) | (11.99M) |
| Pre-Tax Margin | -250.9% | — | -856.8% | — | -2927.3% |
| Income Tax Expense | 2.57K | 2.82K | 3.05K | 5.54K | 5.99K |
| Net Income | (10.13M) | (14.07M) | (8.57M) | (11.05M) | (12M) |
| Net Margin | -251.0% | — | -857.2% | — | -2928.8% |
| EPS (Basic) | (0.21) | (0.29) | (0.17) | (0.23) | (0.24) |
| EPS (Diluted) | (0.21) | (0.29) | (0.17) | (0.23) | (0.24) |
| Weighted Avg Shares | 48.6M | 49.05M | 49.05M | 49.05M | 49.06M |
| Weighted Avg Shares (Diluted) | 48.6M | 49.05M | 49.05M | 49.05M | 49.06M |
MediciNova, Inc.
NASDAQ:MNOV
Intrinsic Alpha fair value
Locked
Current Price
$1.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.